Nouritza Torossian

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

Paul Gougis, Camille Moreau Bachelard, Maud Kamal et al. · JNCI Cancer Spectrum · 2019 · 71 citations · Full text

Medicine, Cancer Biology, Oncology +17

Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells

Annabelle Congras, Nina Caillet, Nouritza Torossian et al. · Oncotarget · 2018 · 24 citations · Full text

Medicine, Cancer Biology, Oncology +16

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets

Aurélie Moreira, Julien Masliah‐Planchon, Céline Callens et al. · European Journal of Cancer · 2019 · 20 citations · Full text

Medicine, Molecular Medicine, Pharmacology +8

Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck

Khalil Saleh, Anne Aupérin, Nicolas Martin et al. · European Journal of Cancer · 2021 · 19 citations

Medicine, Immunology, Oncology +16

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

Pauline Vaflard, Xavier Paolettí, Vincent Servois et al. · Drugs in R&D · 2021 · 19 citations · Full text

Medicine, Oncology, Immunotherapy +13